Targeted Disruption of Ephrin B1 in Cells of Myeloid Lineage Increases Osteoclast Differentiation and Bone Resorption in Mice by Cheng, Shaohong et al.
Targeted Disruption of Ephrin B1 in Cells of Myeloid
Lineage Increases Osteoclast Differentiation and Bone
Resorption in Mice
Shaohong Cheng
1, Shien Lucy Zhao
1, Brittany Nelson
4, Chandrasekhar Kesavan
1,2, Xuezhong Qin
1,2, Jon
Wergedal
1,2,3, Subburaman Mohan
1,2,3,4, Weirong Xing
1,2*
1Musculoskeletal Disease Center, Jerry L Pettis VA Medical Center, Loma Linda, California, United States of America, 2Department of Medicine, Loma Linda University,
Loma Linda, California, United States of America, 3Department of Biochemistry, Loma Linda University, Loma Linda, California, United States of America, 4Department of
Physiology, Loma Linda University, Loma Linda, California, United States of America
Abstract
Disruption of ephrin B1 in collagen I producing cells in mice results in severe skull defects and reduced bone formation.
Because ephrin B1 is also expressed during osteoclast differentiation and because little is known on the role of ephrin B1
reverse signaling in bone resorption, we examined the bone phenotypes in ephrin B1 conditional knockout mice, and
studied the function of ephrin B1 reverse signaling on osteoclast differentiation and resorptive activity. Targeted deletion of
ephrin B1 gene in myeloid lineage cells resulted in reduced trabecular bone volume, trabecular number and trabecular
thickness caused by increased TRAP positive osteoclasts and bone resorption. Histomorphometric analyses found bone
formation parameters were not changed in ephrin B1 knockout mice. Treatment of wild-type precursors with clustered
soluble EphB2-Fc inhibited RANKL induced formation of multinucleated osteoclasts, and bone resorption pits. The same
treatment of ephrin B1 deficient precursors had little effect on osteoclast differentiation and pit formation. Similarly,
activation of ephrin B1 reverse signaling by EphB2-Fc treatment led to inhibition of TRAP, cathepsin K and NFATc1 mRNA
expression in osteoclasts derived from wild-type mice but not conditional knockout mice. Immunoprecipitation with
NHERF1 antibody revealed ephrin B1 interacted with NHERF1 in differentiated osteoclasts. Treatment of osteoclasts with
exogenous EphB2-Fc resulted in reduced phosphorylation of ezrin/radixin/moesin. We conclude that myeloid lineage
produced ephrin B1 is a negative regulator of bone resorption in vivo, and that activation of ephrin B1 reverse signaling
inhibits osteoclast differentiation in vitro in part via a mechanism that involves inhibition of NFATc1 expression and
modulation of phosphorylation status of ezrin/radixin/moesin.
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Introduction
Osteoporosis is an aging-related major health problem in women
and men. There are two major known causes of osteoporosis; low
peak bone mineral density that is typically achieved around the age
of 30, and high bone loss rate which occurs particularly after
menopause and during the natural process of aging. Bone loss
occurs with age in part because the increased bone resorption rate is
not compensated for by the corresponding increase in the bone
formation rate. Therefore, studies to identify the regulatory factors
and their molecular pathways that modulate bone resorption rate
are important to the overall understanding of bone diseases.
Ephrin (A and B) and their receptors have been shown to play
key roles in the growth and development of multiple tissues [1,2,3].
Ephrin As are membrane anchored proteins while ephrin Bs are
transmembrane proteins. In general, ephrin As bind to eprhin A
receptors while ephrin Bs bind to ephrin B receptors (EphBs) with
few exceptions [4]. The interaction of ephrin B with its receptors
via cell-cell contact leads to the activation of a bidirectional signal
in which both the receptors (forward) and the ligand (reverse)
activate downstream signaling cascades [5,6,7,8]. Ephrin B1, B2,
and B3 have the same structure of a single transmembrane
domain, and a well-conserved cytoplasmic domain that includes
33 amino acids with 100% identity [9,10]. Studies in non-bone
cells have shown that the PDZ binding motif, and six tyrosine
residues within the C-terminal 33 amino acids of ephrin B1 and
B2 function as receptor-like signaling molecules which transduce
signals into the interior of the cell through tyrosine phosphoryla-
tion and interaction with PDZ domain-containing proteins
[11,12,13,14]. In addition to tyrosine phosphorylation, there is
also evidence for phosphorylation of serine residues in ephrin B1
by serine/threonine kinases to facilitate binding of adapter
proteins [15]. In our previous studies, we have shown that sodium
hydrogen exchange regulatory factor 1 (NHERF1) interacts with
ephrin B1, recruits other PDZ proteins and mediates transcription
factor TAZ dephosphorylation and nuclear transportation leading
to increased expression of genes that are critical for osteoblast
differentiation [16].
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32887Both ephrin B ligands and their receptors are co-expressed in
osteoblasts, but only ephrin B1 and B2 are expressed during the
osteoclast precursor differentiation [7]. While in vitro studies have
shown that activation of ephrin B2 in osteoclasts inhibited c-Fos
and NFATc1 expression, leading to decreased osteoclast differen-
tiation, specific disruption of ephrin B2 in myeloid lineage cells did
not induce bone resorption or cause bone loss in vivo [7]. The lack
of skeletal phenotype in ephrin B2 conditional knockout (KO)
mice could be due to a functional compensation by ephrin B1
since the C-terminal domains of ephrin B1 and ephrin B2 are
structurally similar. Since little is known on the role of ephrin B1 in
regulating osteoclast functions, we examined if activation/
inactivation of ephrin B1 reverse signaling modulates macrophage
colony-stimulating factor (M-CSF)/receptor activator of nuclear
factor kb ligand (RANKL) signaling and alters mature osteoclast
formation in vivo and in vitro. Our studies found that ephrin B1 was
expressed at a several-fold higher level than ephrin B2 during
osteoclast differentiation, and mice with conditional disruption of
ephrin B1 gene in cells of myeloid lineage had reduced trabecular
bone volume, trabecular number, trabecular thickness, and
increased trabecular separation.
Results
Ephrin B1 is predominantly expressed in osteoclasts
Because both ephrin B1 and ephrin B2 were reported to be
expressed in osteoclasts [7], we compared protein expression levels
of ephrin B1 and ephrin B2 during the differentiation of precursors
to mature multinucleated osteoclasts. Osteoclast precursors
derived from the spleen or non-adherent bone marrow of wild-
type (WT) mice were cultured in the presence of 20 ng/ml of M-
CSF and 30 ng/ml of soluble RANKL for 8 days. Precursors
cultured in the absence of soluble RANKL serve as undifferen-
tiated controls (0 day). As shown in Figure 1A, precursors derived
from non-adherent bone marrow were differentiated to tartrate-
resistant acid phosphatase (TRAP) staining positive, multinucleat-
ed cells (MNC) after 4–8 days of RANKL treatment. A parallel set
of undifferentiated and differentiated osteoclasts were lysed for
Western blot with specific antibodies to mouse ephrin B1, ephrin
B2, and b-actin (Figure 1B). The expression levels of ephrin
B1 protein continued to increase during the differentiation of
osteoclast precursors into mature osteoclasts. The highest
expression of ephrin B1 was found in mature MNCs at day 8
after RANKL treatment. However, the expression of ephrin B2
protein was undetectable when 30 mg of total cellular protein
extracted from the differentiated and undifferentiated osteoclasts
was analyzed by Western blot using a commercial polyclonal
antibody which did recognize recombinant ephrin B2 protein
over-expressed in RAW264.7 positive control cells (data not
shown). To quantify the expression levels of ephrin B1 and ephrin
B2 transcripts during the osteoclast differentiation, we isolated
precursors from mouse spleen, and treated them with M-CSF and
RANKL for 4 days. The cells were then lysed for RNA extraction
and real time RT-PCR. While expression of both ephrin B1 and
Figure 1. Expression of ephrin B1 is increased during osteoclast differentiation. [A–B]: Expression of ephrin B1 is increased during
osteoclast differentiation. Osteoclast precursors isolated from non-adherent bone marrow of wild-type (WT) mice were treated with 20 ng/ml of M-
CSF and 30 ng/ml of RANKL for 0, 2, 4 and 8 days. The differentiated multinuclear cells (MNCs) were monitored by TRAP staining. The parallel cultures
were harvested, and total cellular proteins were extracted for Western blot. [C]: Expression of ephrin B1 is more abundant than ephrin B2 in
osteoclasts. Mouse splenocytes were treated with M-CSF only or M-CSF plus RANKL for 4 days. Total RNA was extracted for real-time PCR. Values are
fold-change over the expression level of ephrin B2 transcript in undifferentiated precursors, and expressed as mean 6 SEM (standard error of mean)
(n=3). A star represents statistical significance of expression level of transcript in MNCs as compared to the precursors or between two groups
indicated (P,0.01).
doi:10.1371/journal.pone.0032887.g001
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compared to undifferentiated cells, expression of ephrin B1 was
15-fold higher than ephrin B2 in undifferentiated precursors after
calibration of PCR amplification efficiencies for ephrin B1 primers
and ephrin B2 primers with cDNA containing plasmid. The
expression level of ephrin B1 was 10 times higher than ephrin B2
in the mature MNCs. Ephrin B2 transcript was increased by 8-fold
in the MNCs while the expression of ephrin B1 was elevated by
5.3 fold in the differentiated osteoclasts as compared to the
undifferentiated precursors (Figure 1C).
Activation of ephrin B1 reverse signaling inhibits
osteoclast differentiation
To determine if activation of ephrin B1 reverse signaling
influences the differentiation of osteoclast precursors into mature
MNCs, bone marrow macrophage precursors were treated with
clustered soluble recombinant EphB2-Fc protein that only
contains extracellular domain of mouse EphB2 receptor, and
can activate ephrin B1 reverse signaling but not EphB2 mediated
forward signaling during day 2–8 or day 5–8 of RANKL-induced
osteoclast differentiation. As shown in Figure 2, eight days of
RANKL treatment induced formation of mature MNCs from the
precursors derived from the WT mice that was inhibited by
exogenous addition of EphB2-Fc. Treatment of osteoclasts with
EphB2-Fc from day 2–8 resulted in greater inhibition of osteoclast
formation than day 5–8. Formation of multinucleated cells with 3–
6, 6–10 and .10 nuclei per cell were reduced by 60%, 80% and
95%, respectively, in bone marrow macrophage precursors treated
with EphB2-Fc during day 2–8 as compared to control Fc.
However, treatment of osteoclast precursors during days 5–8 with
EphB2-Fc caused no significant difference in the formation of
differentiated osteoclasts with 3–10 nuclei while it did decrease
formation of large osteoclasts with more than 10 nuclei per cell by
50%.
Disruption of ephrin B1 gene in cells of myeloid lineage
reduced trabecular bone volume, trabecular number and
bone thickness
To study the functions of ephrin B1 expressed in osteoclasts,
ephrin B1 gene was deleted in cells of myeloid lineage by Cre/loxp
approach (Figure 3A). After 3 generations of breeding, homozy-
gous Lyz2-Cre, loxp homozygous female or hemizygous male mice
were generated, and used as experimental KO mice. Both WT
alleles of Lyz2 gene, loxp homozygous or hemizygous mice served
as controls. To confirm the ephrin B1 expression in the
homozygous Lyz2-Cre, loxp homozygous mice, precursors were
isolated from the spleen of conditional KO and WT mice, and
differentiation was induced by treatments of M-CSF and RANKL.
Total cellular extracts from differentiated osteoclasts were used for
Western blot. As expected, the expression of the ephrin B1 protein
was absent in osteoclasts from homozygous Lyz2-Cre, loxp
homozygous mice, but was detected in the cells from Cre- control
littermates (Figure 3B). In contrast, bone marrow stromal cells
derived from both KO and WT mice expressed high levels of
ephrin B1 protein. To characterize the skeletal phenotypes of
ephrin B1 conditional KO mice, the femurs were collected from
21 week old mice and analyzed trabecular structures by m-CT
analyses (Figures 4A–B). While there was no significant difference
in cortical mineral density at the mid diaphysis of the femur of WT
and KO mice (data not shown), the ratio of trabecular bone
volume to total volume (BV/TV) was reduced by 40% at the
metaphysis of the femur from the mixed genders of KO mice as
compared to the littermate controls (Figure 4C). Trabecular
number and trabecular thickness were reduced by 23% and 18%,
respectively, while trabecular separation was increased by 24% at
this site of the femurs isolated from KO mice (Figures 4 D–F).
There was no significant difference in the magnitude of trabecular
bone volume reduction in the KO mice between the two genders
(data not shown).
To identify the target cell types and cellular processes that
contribute to reduced trabecular bone volume of the distal femurs
in the ephrin B1 conditional KO mice, histomorphometric studies
were performed in KO and control mice. Figure 5 shows the data
from TRAP staining for trabecular bone surfaces examined at
distal metaphysis of the femurs of mixed genders of 21 week old
mice (N=8 with 50% females and 50% males). Two longitudinal
sections from the middle sampling site of the femur were TRAP-
stained. Total trabecular surface and TRAP positive tabecular
surface in 7 microscope fields per section were blindly quantified
with OsteoMeasure software. We found that the percentage of
TRAP labeled surface to bone surface at the metaphysis was
increased by 26% in the conditional KO mice as compared to the
littermate controls (Figures 5A–C). In addition, the serum TRAP
activity, a bone resorption marker, was also elevated by 28% in the
KO mice (Figure 5D). We next determined if loss of ephrin B1 in
cells of myeloid lineage influences bone formation. We found there
was no significant difference in newly formed bone between two
calcein labels in the KO mice as compared to control mice
(Figures 5E & F). The bone size was not affected in the KO mice
(data not shown). Bone formation rate/bone surface (BFR/BS)
and mineral apposition rate (MAR) were not significantly altered
(Figures 5G & H). The lack of difference in bone formation
between conditional KO and WT mice was not surprising because
conditional disruption of ephrin B1 in cells of myeloid lineage did
Figure 2. Activation of ephrin B1 reverse signaling suppresses
osteoclast differentiation. [A]: Osteoclast precursors derived from
WT mice were differentiated in the presence of 20 ng/ml of M-CSF and
30 ng/ml of RANKL for 8 days. The cells were also treated with clustered
EphB2-Fc during day 2–8 or day 5–8 of the culture as indicated in the
figure, followed by TRAP staining. [B]: Quantitative data of TRAP
positive MNCs. Values are mean 6 SEM (n=8). A star presents statistical
significance of MNCs in the differentiated cultures treated with EphB2-
Fc as compared to the cultures treated with control Fc (P,0.01).
doi:10.1371/journal.pone.0032887.g002
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as shown by Western blot analyses (Figure 3B).
Activation of ephrin B1 reverse signaling inhibits
osteoclast differentiation and bone resorption
To examine whether lack of ephrin B1 expression and ephrin
B1 reverse signaling influences osteoclast differentiation, spleno-
cytes were isolated from WT and ephrin B1 conditional KO mice,
and induced to differentiate in the presence of M-CSF and
RANKL. Cells were also treated with EphB2-Fc or control Fc at
day 2 through 10, followed by TRAP staining. Multinucleated
cells were counted under the microscope. As shown in Figures 6A
& B, treatment of WT precursors with EphB2-Fc suppressed
MNCs formation by 49.8% while the same treatment of ephrin B1
deficient cells with EphB2-Fc had little effect on osteoclast
differentiation as compared to Fc control treatment. To further
test the effect of ephrin B1 reverse signaling on osteoclast function,
bone resorption pit assay was performed. Osteoclast precursors
were seeded on the top of bone slices in the presence of M-CSF
and RANKL, and treated with EphB2-Fc or control Fc in the
same way as described above. After 10 days of culture, bone
resorption pits were stained and the resorption areas were
analyzed. As shown in Figures 6C & D, treatment of WT
osteoclast precursors with EphB2-Fc inhibited area of resorption
pits by 54% as compared to the cells treated with control Fc. In
addition, the size of individual resorption pits appeared smaller in
the EphB2-Fc treated cultures as compared to Fc controls.
However, the same treatment of ephrin B1 deficient cells did not
show a significant effect on pit formation.
To examine whether activation of ephrin B1 reverse signaling
influences expression of osteoclast differentiation marker genes,
splenocytes derived from WT mice were cultured in the presence
of RANKL and M-CSF for 24 hours, and then treated with
soluble EphB2-Fc or control Fc for another 4 days. Total RNA
was extracted for RT real-time PCR. As shown in Figure 7A,
expression of TRAP gene was reduced by 62% in the
Figure 3. Conditional ephrin B1 KO is myeloid-lineage specific.
[A]: Schematic diagram of generation of ephrin B1 conditional KO and
control WT. Mice with ephrin B1 deletion in myeloid lineage cells are
generated by crossing ephrin B1 loxp mice with Lyz2-Cre knock-in mice.
[B]: Ephrin B1 is not expressed in osteoclasts from the myeloid-specific
conditional KO mice. Splenocytes derived from WT and KO mice were
cultured in the presence of 20 ng/ml of M-CSF and 30 ng/ml of RANKL
for 3 days. Bone marrow stromal (BMS) cells isolated from the long
bones were also cultured in a-MEM medium containing 10% FBS for 6
days. Osteoclasts (OC) and BMS cells were harvested, respectively, and
the cellular proteins were extracted for measurement of ephrin B1
protein, by Western blot.
doi:10.1371/journal.pone.0032887.g003
Figure 4. Ephrin B1 deletion in cells of myeloid lineage
decreases trabecular bone. [A]: Longitudinal section of m-CT images
of distal femurs of WT and KO mice. The metaphysis of distal femurs
were selected for analyses of trabecular bone parameters by m-CT. [B]:
m-CT images of trabecular bone of the distal metaphysis of the femurs.
[C–F]: Quantitative measurements of trabecular bone at the metaphysis
of distal femurs. [C]: Percentage change of trabecular bone volume/
total bone volume (BV/TV) of the distal femur of KO mice as compared
to WT littermate controls. [D]: Percentage change of trabecular number
(Tb. N) of the distal femur of KO mice as compared to WT littermate
controls. [E]: Percentage change of trabecular thickness (Tb. Th) of the
distal femur of KO mice as compared to WT littermate controls. [F]:
Percentage change of trabecular separation (Tb. Sp) of the distal femur
of KO mice as compared to WT littermate controls. Values are expressed
as mean 6 SEM (n=8). A star presents statistical significance (P,0.05)
as compared to WT littermate controls.
doi:10.1371/journal.pone.0032887.g004
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compared to the control cells treated with Fc, but there was no
change in TRAP expression between the treatments in the
undifferentiated precursors (data not shown). Similarly, EphB2-Fc
treatment inhibited the expression of cathepsin K (CatK) and
NFAFc1 by 60% and 67%, respectively, in WT osteoclasts,
however not in the ephrin B1 deficient cells. There was little
change in c-Fos expression in the WT cells treated with EphB2-Fc
as compared to the cells treated with Fc (data not shown).
Activation of ephrin B1 reverse signaling stimulates
ephrin B1 interaction with NHERF1, and ezrin/radixin/
moesin inactivation
Because the ezrin, radixin and moesin (ERM) proteins function
as linkers between the plasma membrane and the actin cytos-
keleton, and phosphorylation of ERM is involved in cytoskeletal
rearrangement and cell migration [17,18,19,20], and because
NHERF1 expressed in osteoclasts associates with ezrin and actin
[21], we predicted that activation of ephrin B1 reverse signaling
would affect intra or intermolecular interaction between ERM
amino- and carboxyl-terminal domains via complex formation of
ephrin B1, NHERF1 and PDZ containing phosphatase. To test if
ezrin expression and phosphorylation of ERM proteins were
changed during osteoclast differentiation, total cellular proteins
were extracted from different stages of osteoclast differentiation for
immunoblot with specific antibodies against total ezrin, phosphor-
ERM and total ERM. Western blot analyses with antibody against
total ezrin detected two species of ezrin protein with molecular
weights around 80 kDa. While the total ezrin was not changed
during the differentiation of precursors into mature osteoclasts,
larger molecular weight of ezrin proteins was increased at day 2,
reached its peak at day 4 and maintained at highest level at day 8
in multinucleated cells (Figure 7D). In contrast, ezrin with smaller
molecular mass was decreased in differentiated osteoclasts (days 4
& 8) as compared to the undifferentiated precursors (day 0). In
addition, specific antibody against phosphorylated ERM at a
carboxyl-terminal residue (threonine 567 of ezrin, threonine 564
of radixin, threonine 558 of moesin) detected elevated levels of
active form of phosphorylated ERM in differentiated multinucle-
ated cells as compared to the undifferentiated control cells (day 0).
To examine the interaction of ephrin B1 with NHERF1 in
differentiated osteoclasts, we stimulated the cells with clustered
EphB2-Fc for 5 min, cross-linked with dithiobis (succinimidyl)
propionate, and lysed for immunoprecipitation with anti-
NHERF1. As shown in Figure 7E, we were able to immunopre-
Figure 5. Ephrin B1 deletion in cells of myeloid lineage increases bone resorption. [A–B]: TRAP staining of osteoclasts at trabecular surface
of metaphysis of the femur in WT and KO mice at 21 weeks of age. Bone section was counterstained with methyl green. Arrows denote representative
TRAP positive osteoclasts. A: 206magnification, B: 1006magnification. [C]: Percentage change of TRAP labeled surface/trabecular bone surface (Oc.
S/BS) in the bone of ephrin B1 KO mice as compared to WT controls at 21 weeks of age. Values are presented as mean 6 SEM (n=8). [D]: Percentage
change of serum TRAP activity of ephrin B1 KO mice as compared to WT controls at 21 weeks of age. Values are presented as mean 6 SEM (n=8). [E–
F]: Trabecular bone formation is unaffected in mice with deletion of ephrin B1 in myeloid lineage cells. E: Images of H & E staining of distal femurs of
WT and KO mice (206). F: representative images of calcein double labeled trabecular bone of WT and KO mice (2006). [G–H]: Quantitative data of
trabecular bone formation measured at distal femur metaphysis of WT and KO mice at 21 weeks of age. G: Bone formation rate/bone surface (BFR/
BS). Values are presented as mean 6 SEM (n=8). H: Mineral apposition rate (MAR). Values are presented as mean 6 SEM (n=8).
doi:10.1371/journal.pone.0032887.g005
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differentiated osteoclasts. To further test if activation of ephrin
B1 changes ERM phosphorylation at C-terminus of threonine
residues in differentiated osteoclasts, osteoclast precursors were
differentiated for 4 days, and then the differentiated cells were
treated with 2 mg/ml of EphB2-Fc or Fc for 24 hours. Total
cellular protein was extracted for Western blot with specific
antibodies to total ERM and phosphorylated form of ERM (p-
ERM). We found that activation of ephrin B1 by EphB2-Fc
treatment inhibited ERM phosphorylation in the WT osteoclasts,
but not in the ephrin B1 deficient cells (Figure 7F).
Discussion
Ephrin B1 is expressed in various types of cells and plays key
roles in the growth and development of multiple tissues
[1,2,22,23,24,25]. Although ubiquitous deficiency of ephrin B1
in every types of cells or in epiblast during early embryogenesis
results in prenatal lethality and skeletal defects in mice [1,5], and
conditional KO of ephrin B1 gene in collagen I producing cells
leads to calvarial defects and reduced bone formation [16], little is
known on the role of ephrin B1 produced during osteoclast
differentiation and maturation. In this study, we show that ephrin
B1 was predominantly expressed in osteoclast precursors and
differentiated osteoclasts. Ephrin B1 expression was increased at
both mRNA and protein levels during the differentiation of
precursors to multinucleated osteoclasts. We also used knock-in
mice expressing a Cre recombinase under the control of
endogenous Lyz2 regulatory elements to disrupt ephrin B1 in
cells of myeloid lineage, and examined the consequence of
conditional disruption of ephrin B1 on the skeletal phenotypes in
vivo. We show that KO of ephrin B1 in osteoclast precursors was
complete, and the conditional KO in myeloid lineage cells did not
influence ephrin B1 expression in bone marrow stromal cells.
Targeted disruption of ephrin B1 in cells of myeloid lineage
resulted in decreased trabecular number, trabecular thickness, and
trabecular bone volume but increased trabecular separation. The
reduced trabecular bone in ephrin B1 conditional KO mice was
caused by increase in osteoclast differentiation and bone
resorption. Our in vitro studies also demonstrate that interaction
Figure 6. Activation of ephrin B1 reverse signaling inhibits osteoclast formation and bone resorption. [A]: Interaction of ephrin B1 with
EphB2-Fc suppresses osteoclast differentiation. Splenocytes from WT and ephrin B1 KO mice were cultured in the presence of RANKL and M-CSF for
24 hours, and then treated with soluble EphB2-Fc (2 mg/ml) or control Fc for 8 days. TRAP staining was performed after 6 days EphB2-Fc treatment.
MNCs were visualized under microscope. [B]: Quantification of MNCs (3 or more nuclei per cell). Values are mean 6 SEM (n=8). A star presents
statistical significance (P,0.01) as compared to the cells treated with control Fc. [C]: Interaction of ephrin B1 with EphB2-Fc suppresses bone
resorption. Splenocytes from WT and ephrin B1 KO mice were seeded on bone slices, and cultured in the presence of RANKL and M-CSF for 24 hours,
and then treated with EphB2-Fc or control Fc for additional 8 days. Resorption pits on bone slices were analyzed after 8 days of EphB2-Fc treatment.
[D]: Quantification of resorption pit areas. Values are mean 6 SEM (n=6). A star presents statistical significance (P,0.01) as compared to the cells
treated with control Fc.
doi:10.1371/journal.pone.0032887.g006
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ylation, osteoclast differentiation and resorption pit formation.
The findings indicate that ephrin B1 predominantly produced in
osteoclasts is an important regulator of osteoclast differentiation,
bone resorption and trabecular bone volume.
Ephrin B1, B2 and B3 share the same structure of a single
transmembrane domain, and a well-conserved cytoplasmic do-
main that includes 33 amino acids with 100% identity [9,10].
Among ephrin B proteins, B1 and B2 have been shown to be
expressed in bone cells [5,7]. In terms of ephrin B1 and B2
functions, Zhao et al. generated conditional ephrin B2 KO mice
by crossing ephrin B2 loxp mice with Lyz2-Cre, and examined the
bone phenotypes in vivo. Although their studies demonstrated a
critical role of ephrin B2 reverse signaling in osteoclast
differentiation, mice with disruption of ephrin B2 in cells of
myeloid lineage cells failed to show a significant increase in bone
resorption [7]. This study suggested that other ephrin B ligands
may compensate for the loss of ephrin B2 function in osteoclasts in
vivo. In our studies, we found that while ephrin B2 protein levels
were below detectable limit in both undifferentiated and
differentiated osteoclasts in our culture condition, the expression
of ephrin B1 protein was significantly elevated in osteoclast
precursors, and was further increased during the osteoclast
differentiation. Our result of Western blot was inconsistent with
previous studies which demonstrate expression of ephrin B2 in
differentiated osteoclasts [26]. One potential explanation for the
Figure 7. Activation of ephrin B1 reverse signaling inhibits phosphorylation of ezrin/radixin/moesin and RANKL target gene
expression in osteoclasts. [A–C]: Treatment of EphB2-Fc inhibits expression of osteoclast differentiation marker genes. Precursors were cultured in
the presence of RANKL and M-CSF for 24 hours, and then treated with soluble EphB2-Fc (2 mg/ml) or control Fc for another 4 days. Total RNA was
extracted for real-time RT-PCR using specific primers to TRAP, cathepsin D (CatK) and NFATc1. Values are expressed as fold change over WT cells 6
SEM (n=3). A star presents statistical significance (P,0.05) as compared to the cells derived from WT littermate mice. [D]: ERM phosphorylation is
increased during RANKL induced osteoclast differentiation. Splenocytes from WT mice were treated with 20 ng/ml of M-CSF and 30 ng/ml of RANKL
for 0, 2, 4 and 8 days. Total cellular proteins from osteoclasts were extracted for Western blot. [E]: Ephrin B1 interacts with NHERF1 in osteoclasts.
Splenocytes were treated with M-CSF and RANKL for 4 days. Cells were then treated with EphB2-Fc for 5 minutes, and used for immunoprecipitation.
[F]: Activation of ephrin B1 reverse signaling inhibits ERM phosphorylation. Splenocytes derived from ephrin B1 KO and WT mice were treated with
M-CSF and RANKL for 4 days, and then the cells were treated with 2 mg/ml of EphB2-Fc or Fc in differentiation medium for another 24 hours. Total
cellular proteins were extracted for Western blot.
doi:10.1371/journal.pone.0032887.g007
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(30 mg) we used was not sufficient to detect low levels of
endogenous ephrin B2 by Western blot with low affinity ephrin
B2 antibody while the same dilution of antibody could detect the
high concentration of over-expressed ephrin B2 protein in the cell
extract from our culture system. Furthermore, loss of ephrin B1
did not cause up-regulation of ephrin B2 in osteoclast precursors.
Accordingly, activation of ephrin B1 reverse signaling by EphB2-
Fc treatment inhibited osteoclast differentiation in ephrin B1
producing WT cells, but not in ephrin B1 deficient cells. Our in
vitro data together with in vivo data showing phenotypes of reduced
trabecular bone volume in ephrin B1 conditional KO mice
provide strong evidence that the amount of ephrin B2 protein in
osteoclasts cannot compensate for the loss of ephrin B1 on the
skeletal phenotype in the ephrin B1 conditional KO mice, and
explain why mice with conditional KO of ephrin B2 in osteoclasts
did not exhibit a bone phenotype.
In our previous studies, we have demonstrated that bone
marrow stromal cells and calvarial osteoblasts express both ephrin
B1 and its cognate EphB2 receptor [16]. Besides EphB2, ephrin
B1 also preferentially binds B3 receptor with high affinity and
interacts with EphB1, B4 and A4 receptors with low affinity
[4,7,27,28]. In the cells that co-express both ephrin ligand and its
receptors, the ephrin ligand and receptor proteins can be
segregated into distinct membrane domains from which they
signal biological effects via cell surface interactions [6]. Thus, both
forward and reverse signals are feasible upon contact of osteoclast
to osteoblast or mesenchymal stem cell on the bone surface. In this
regard, recent studies found that ephrin B2 produced by
osteoclasts might interact with EphB4 receptor in osteoblasts to
induce forward signaling and osteoblast differentiation [7], and
EphB2 mediated forward signaling promoted human mesenchy-
mal stem cell migration [29]. On the other hand, it has been
reported that ephrin B1/EphB3 mediated forward signaling acts
as a mitogen to regulate palatal shelf mesenchymal cell
proliferation via activation of the ERK/MAPK signaling pathway
[27]. In the mouse small intestine and colon, EphB2 signaling
directs stem cell migration, promotes cell-cycle reentry of
progenitor cells and stimulates cell proliferation [22]. Accordingly,
these studies indicate that functions of ephrin/Eph forward
signaling are complex and depend on the target tissue and cell-
types. The relative contribution of eprhin/Eph forward signaling
in skull development, bone formation and bone resorption is not
well understood. In our studies, we did not observe impaired bone
formation in mice with disruption of ephrin B1 gene in myeloid
lineage cells. Instead, we found a slight, but not significant increase
in bone formation. The slight increase in bone formation could be
a compensatory effect to increased bone resorption. In addition,
osteoblasts and mesenchymal stem cells express abundant eprhin
B1 protein which can compensate for the loss of ephrin B1
produced in osteoclasts, and interact with its receptors on the
membrane of neighboring cells. Thus, our observation that
trabecular bone volume was diminished in the ephrin B1
conditional KO mice cannot be explained because of lack of
receptor-mediated forward signaling in the bone.
Rapid cytoskeletal reorganization is essential for osteoclast
function and formation of the specialized membranes. Recent
studies have found that NHERF1 expressed in osteoclasts co-
localizes with type IIa Na/Pi contransporter (Npt2a) and actin at
the plasma membrane and associates with ezrin and actin for
membrane sorting [21]. Targeted disruption of NHERF1 results
in postnatal lethality often accompanied by bone fractures due to
25–30% reduction in bone mineral density [30] while targeted
disruption of Npt2a only showed mild skeletal phenotype that is
improved with age [31]. The severity of skeletal phenotype in the
NHERF1 KO mice cannot be explained by the sole function of
NHERF1 to redistribute Npt2a for phosphate transport in the
kidneys, thus suggesting that NHERF1 has other functions such as
modulation of osteoclast differentiation and bone resorption [21].
Moreover, interaction of NHERF1 with PDGFR-b through its C-
terminal PDZ binding motif modulates PDGF-induced cell
spreading and motility [32,33], and the formation of a ternary
complex between PTEN, NHERF1 and PDGFR have been
reported to attenuate PDGF-induced cytoskeletal rearrangements
and chemotactic migration of the cells [34]. In terms of the
molecular pathway of ephrin B1 in bone cells, we previously
demonstrated that ephrin B1 interacts with PTPN13 and
NHEFR1 in bone marrow stromal cells [16]. Here, we show that
ephrin B1, which is structurally similar to PTEN, also interacts
with NHERF1 in osteoclasts, and treatment of osteoclast with
EphB2-Fc leads to reduced phosphorylation of ERM proteins.
Because NHERF1 can interact with both cytoplasmic PDZ
domain of membrane proteins and N-terminus of ezrin [35], it
is reasonable to assume that the interaction of ephrin B1 with
NHERF1 could disrupt the intramolecular interaction of ‘‘head-
to-tail’’ of NHERF1, and stabilize it in an ‘‘open’’ conformation so
that C-terminal ERM binding motif of NHERF1 can associate
with ERM with high affinity at the osteoclast membrane [36].
Studies in endothelial cells have also revealed that C-terminal PDZ
motif of G protein coupled receptors and membrane iron channels
can recruit PDZ domain-containing protein phosphatase PP2A
and NHERF1 at the apical surface to form scaffold protein
complex [35,37,38]. Therefore, it is possible that complex
formation of ephrin B1, NHERF1 and ERM facilitates ezrin
dephosphorylation via PP2A and modulates the lateral mobility of
osteoclast precursors. Furthermore, clustered ephrin B1 polymers,
NHERF1, Npt2a, and/or Na
+/H
+ exchanger 3 may form scaffold
complex for regulation of membrane sorting, apical membrane
mobility and Na
+/H
+/Pi transport in osteoclasts when osteoclasts
contact osteoblasts on the bone surface [21,34,35]. In support of
these hypotheses, our experiments show that the ERM inactiva-
tion is associated with reduced osteoclast size, and resorptive
activity. Activation of ephrin B1 reverse signaling also inhibited
TRAP, cathepsin K and NFATc1 expression. Our data suggest
that besides ephrin B1 reverse signaling regulates the expression of
NFATc1, it also modulates phosphorylation of ERM proteins
which have been shown to be involved in the rearrangement of
actin cytoskeleton in neuronal morphogenesis [20]. Further studies
are needed to determine whether activation of ephrin B1 reverse
signaling regulates osteclast differentiation and bone resorption via
rearranging cytoskeleton, and whether PDZ domain containing
phosphatase such as PP2A is involved in the ephrin B1/NHERF1
complex formation and mediates ERM dephosphorylation.
Materials and Methods
Recombinant proteins and antibodies
Recombinant proteins of control Fc and EphB2-Fc, anti-human
IgG, anti-NHERF1 and anti-b-actin were purchased from Sigma (St.
Louis, CO). Recombinant proteins of M-CSF and RANKL, anti-
ephrin B1, anti-ephrin B2, anti-RANK and anti-M-CSR were from
R & D Systems (Minneapolis, MN). Anti-ezrin, anti-ezrin/radixin/
moesin and anti-phospho-ezrin (Thr567)/radixin (Thr564)/moesin
(Thr558) were products of CellSignaling Technology (Danvers,MA).
Generation of mutant mice
The floxed ephrin B1 mice with mixed background of C57BL/
6J and 129S4 strains were kindly provided by Dr. Philippe Soriano
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(Cre) were purchased from The Jackson Laboratory (Bar Harbor,
Main)[39].TogenerateconditionalKOmicethatlackephrinB1in
cells of myeloid lineage, efnb1
flox/flox female was first crossed with
LyZ2
Cre/Cre male to generate LyZ2
Cre/Wt/Efnb1
loxp/wt females.
LyZ2
Cre/Wt/Efnb1
loxp/wt females were then bred with efnb1
flox/Y
hemizygous males to generate LyZ2
Cre/Wt/Efnb1
loxp/loxp females
and with LyZ2
Cre/Wt/Efnb1
loxp/Y males. In subsequent breeding,
LyZ2
Cre/Wt/Efnb1
loxp/loxp females were crossed with LyZ2
Cre/Wt/
Efnb1
loxp/Y males. Our breeding strategy should yield 25% of
LyZ2
Cre/Cre/Efnb1
loxp/Y males and LyZ2
Cre/Cre/Efnb1
loxp/loxp
females (KO), 50% of LyZ2
Cre/Wt/Efnb1
loxp/Y males and
LyZ2
Cre/Wt/Efnb1
loxp/loxp females (Heterozygous Cre), and 25%
of LyZ2
Wt/Wt/Efnb1
loxp/Y males and LyZ2
Wt/Wt/Efnb1
loxp/loxp
females (WT) mice. We excluded Lyz2-Cre heterozygous mice for
experiments because Cre expression in these mice may be low and
insufficient to delete ephrin B1 gene. Genotyping of the ephrin B1
gene and LyZ2 locus were monitored by PCR using DNA extracted
from tail snips as reported [5,16,39]. All mice were housed at the
Jerry L. Pettis Memorial VA Medical Center Veterinary Medical
Unit (Loma Linda, CA) under standard approved laboratory
conditions with controlled illumination (14 hours light, 10 hours
dark), temperature (22uC) and unrestricted food and water. All of
the procedures were performed with the approval of the
Institutional Animal Care and Use Committee (IACUC) of the
Jerry L Pettis Memorial VA Medical Center.
Evaluation of bone phenotypes
Micro-architectures of the femurs isolated from 21-week old mice
were assessed by m-CT (Scanco Invivo CT40, Switzerland) as
described previously [16,40]. Routine calibration was performed
once per week using a three-point calibration phantom correspond-
ing to the density range from air to cortical bone. The femurs were
fixed in10%formalin overnight, washed with PBS and immersed in
PBS to prevent them from drying. The bone was scanned by X-ray
at 55 kVp volts (trabecular bone) or at 75Kvp volts (cortical bone) at
a resolution of 10.5 mm/slice. To minimize the position error (slice
positioning) and to be consistent in our sampling site from mouse to
mouse, we undertook several precautionary steps, which include: 1)
the use of scout view of the whole femur to determine landmarks
and precise selections of measurement sites; 2) the use of the growth
plate of the distal femurs as the reference point; 3) use of a
0.525 mm sampling site that represented 0.315 mm away from the
growth plate for measurement of trabecular bone parameters, and
4)theuse ofa 1.05 mmsampling site thatrepresented 5.5 mmaway
from growth plate for measurement of cortical bone parameters.
Afteracquiringtheradiographicdata,imageswerereconstructedby
using 2-D image software provided by Scanco. The area of the
trabecularanalysiswasoutlinedwithinthe trabecularcompartment.
Every 10 sections were outlined, and the intermediate sections were
interpolated with the contouring algorithm to create a volume of
interest, followed by 3-D analyses using Scanco in vivo software.
Parameters such as bone volume (BV, mm
3), bone volume fraction
(BV/TV, %), trabecular number (Tb.N, mm2
1), trabecular
thickness (Tb.Th, mm) and trabecular separation (Tb.Sp, mm) were
evaluated. The bones analyzed were adjusted for length so that the
regions of interest chosen for cortical and trabecular bone
parameters were anatomically the same if there is a difference in
bone length between the mutant mice and control littermates.
Dynamic calcein labeling and histomorphometry
Twenty-one week-old mice were injected intraperitoneally with
calcein eight days (20 mg/kg) and two days prior to the expected
day of euthanization in order to label mineralizing bone surface.
Mouse femurs were fixed in 10% formalin overnight. The bones were
washed, dehydrated, embedded in methyl methacrylate resin for
sectioning. Longitudinal sections of comparable anatomic position of
the femurs were analyzed by fluorescence microscopy. For analysis of
trabecular bone formation parameters, distal metaphysis of left femurs
were used as a sampling site. For evaluation of bone resorption
parameters, the right femurs were partially demineralized, embedded
in glycomethacrylate and cut into sections. Seven microscope fields
per bone section that cover all trabecular bones of the metaphyseal
region of the distal femur were used for the TRAP surface
measurement. We excluded cortical bone and the trabecular bone
that is adjacent to growth plate since active remodeling is taking place
at this place. The postcoupling method with Napthol-AS-BI
phosphate was used as the substrate and diazotized pararosaniline
w a ss e r v e da st h ec o u p l i n gr e a g e n tt os t a i nf o rT R A Pa c t i v i t y .T w o
middle longitudinal sections per animal were stained and counted.
The trabecular surface and the TRAP labeled trabecular surface were
measured in a blinded fashion with computer software OsteoMeasure
(Osteometrics, Inc. Decatur, GA) by our histomorphological core
facility [41,42]. Mineral apposition rate, bone formation rate/bone
surface were calculated as described previously [43].
Serum TRAP activity assay
Mouse sera were collected from 21-week old mice as described
above. Total serum TRAP activity was measured as previously
reported [44].
In vitro osteoclast formation
Primary osteoclast precursors were isolated from the spleen or
bonemarrowoflongbones(femurandtibia)of5-weekoldephrinB1
conditional KO mice and corresponding control littermates as
described previously [45]. The isolated precursors are maintained in
a-MEMsupplementedwith 10%fetal bovine serum(FBS),penicillin
(100 units/ml), streptomycin (100 mg/ml), and macrophage colony
stimulating factor (M-CSF) (20 ng/ml) at 37uCi n5 %C O 2 for 2
days to stimulate monocyte proliferation. To induce osteoclast
differentiation, trypsinized precursors were seeded to 96-well plates
(2500 cells/well) or 48-well plates (5000 cells/well), and incubated
with M-CSF (20 ng/ml) and RANKL (30 ng/ml). The medium was
changed every 2 days. Osteoclastogenesis was evaluated by counting
TRAP staining positive, multinucleated cells with more than three
nuclei after TRAP staining (Sigma Aldrich, St. Louis, MO).
RNA extraction and quantitative PCR
RNA was extracted from primary osteoclast cultures as described
previously [40,45]. An aliquot of RNA (2 mg) was reverse-
transcribed into cDNA in 20 ml volume of reaction by oli-
go(dT)12–18 primer. Real time PCR contained 0.5 ml template
cDNA, 16 SYBR GREEN master mix (ABI), and 100 nM of
specific forward and reverse primers in 25 ml volume of reaction.
Primers for peptidyl prolyl isomerase A (PPIA) were used to
normalize the expression data of interest genes. Sequences of the
primers used are listed in Table 1. PCR amplification efficiencies
with specific primers to mouse ephrin B1 and ephrin B2 were
calibrated using different copy numbers of plasmids of pMX-ephrin
B2 and pMX-ephrin B1.In repeat realtime PCRusingknown copy
numbers of ephrin B1 and ephrin B2 plasmids, the difference in
PCR amplification efficiency for the two sets of ephrin B1 and
ephrin B2 primers was within 10% with almost same delta CT.
Bone resorption pit assay
Slices from bovine cortical bone were placed in the bottom of
24-wells and cells were seeded on top of bone slices. Cells on bone
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slices were stained with hematoxylin. The entire surface of each
bone slice was examined and the total resorbed area per bone slice
was quantified using ImageJ (National Institutes of Health).
Immunoprecipitation
Cultured osteoclasts were lysed with lysis buffer (50 mM
HEPES [pH 7.5], 100 mM NaCl, 10 mM EDTA, 10% glycerol,
1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 16
protease inhibitor cocktail and 16phosphatase inhibitor cocktail).
Cell lysate (300 mg of total protein) was first precleared by using
protein A/G-Sepharose and then incubated with 4 mg of first,
antibody specific to NHERF1 or control IgG for 1 hour at 4uC
with gentle shaking, followed by the addition of protein A/G-
Sepharose and an additional overnight incubation at 4uC. After
centrifugation, the protein A/G-Sepharose beads were washed five
times with cold lysis buffer and then boiled with SDS-PAGE
sample buffer to dissociate the proteins. The immunoprecipitated
proteins were separated by SDS-PAGE under reducing conditions
for Western Blot with antibodies against ephrin B1 [16].
Western blot analyses
Cultured osteoclasts were lysed as described above. Cell lysate
(30 mg of total cellular protein) was separated by 8–10% SDS-
PAGE under reducing conditions for Western Blot with specific
antibodies against ephrin B1, ezrins, and b-actin as described
previously [46].
Statistical analysis
Data were analyzed using Student’s T-test or ANOVA (one-way
or two way) (Statistica 6, Tulsa, OK) as appropriate.
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